StockNews.AI
RNXT
StockNews.AI
153 days

RenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025

1. RenovoRx will present new pré-clinical data at the SSO 2025 Annual Meeting. 2. This could enhance visibility and interest in RNXT's oncology offerings.

2m saved
Insight
Article

FAQ

Why Bullish?

Presenting at a major conference can attract investor interest. Historically, successful presentations have resulted in positive stock movements for biotech companies.

How important is it?

The announcement of new data at a significant oncology meeting indicates potential advancements in RNXT's product pipeline, which could lead to greater market confidence.

Why Short Term?

The presentation is imminent, likely generating immediate market interest. Initial reactions to such data often occur quickly.

Related Companies

BMYMRKAZN
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, is proud to announce a presentation of a new pre-clinical clinical data abstract at the upcoming Society of Surgical Oncology (SSO) 2025 Annual Meeting. The abstract, titled “Pharmacodynamics of Intra-arterial vs. Intravenous Gemcitabine in Locally.

Related News